Y; providing foreign exchange advisory services, pursuant to § 225.25(b)(17) of the Board's Regulation Y; and Southeast Switch, Inc., and thereby engage in owning an interest in an interbank electronic funds transfer computer network for automatic teller machines, pursuant to § 225.25(b)(7) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, September 25, 1995

William W. Wiles,

Secretary of the Board.

[FR Doc. 95–24248 Filed 9–28–95; 8:45 am]

BILLING CODE 6210–01–F

Peoples Banking Company, et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than October 23, 1995.

A. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. Peoples Banking Company, Springfield, Missouri; to become a bank holding company by acquiring 100 percent of the voting shares of Peoples Bank of the Ozarks, Nixa, Missouri; Citizens Bank of the Ozarks, Camdenton, Missouri; and Peoples Bank of Fordland, Fordland, Missouri.

Comments regarding this application must be received not later than October 13, 1995.

B. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. Park Bank Corporation of Duluth, Duluth, Minnesota; to become a bank holding company by acquiring 100 percent of the voting shares of Park State Bank, Duluth, Minnesota.

Board of Governors of the Federal Reserve System, September 25, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95–24249 Filed 9–28–95; 8:45 am]

BILLING CODE 6210–01–F

Sun Bancorp, Inc.; Notice of Application to Engage de novo in Permissible Nonbanking Activities

The company listed in this notice has filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can ''reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices.'' Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 13, 1995.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. Sun Bancorp, Inc., Selinsgrove, Pennsylvania; to acquire Mifflin Place Associates, Mifflinburg, Pennsylvania, and thereby engage *de novo* in community development activities through a 95 percent investment in Company, pursuant to § 225.25(b)(6) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, September 25, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95–24250 Filed 9–28–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 95N–0317]

Colgate-Palmolive Co., et al.; Withdrawal of Approval of 23 New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 23 new drug applications (NDA's). The holders of the NDA's notified the agency in writing that the drug products were no longer being marketed under the NDA and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: September 29, 1995.

FOR FURTHER INFORMATION CONTACT: Nancy G. Maizel, Center for Drug Evaluation and Research (HFD–53), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2623.

SUPPLEMENTARY INFORMATION: The holders of the NDA's listed below have informed FDA that these drug products are no longer being marketed under the NDA and have requested that FDA withdraw approval of the applications. The applicants have also, by request, waived their opportunity for a hearing.

NDA No.	Drug	Applicant
6–615	Veto Cream Deodorant	Colgate-Palmolive Co., P.O. Box 1343, 909 River Rd., Piscataway, NJ 08855–1343.
7–871	Perazil Cream	Burroughs Wellcome Co., 3030 Cornwallis Rd., P.O. Box 12700, Research Triangle Park, NC 27709–2700.
8–842	Raudixin Tablets	Apothecon, Bristol-Myers Squibb Co., P.O. Box 4500, Princeton, NJ 08543–4500.
10–653	Disipal Tablets	Riker Laboratories Inc., 3M Pharmaceuticals, 270–3A–01 3M Center, St. Paul, MN 55144–1000.
12–026	Apresoline-Esidrix Tablets	Ciba Pharmaceuticals Division, Ciba-Geigy Corp., 556 Morris Ave., Summit, NJ 07901–1398.
12–402	Ivadantin Injection	Procter & Gamble Pharmaceuticals, Regulatory and Clinical Development, Sharon Woods Technical Center, 11370 Reed Hartman Hwy., Cincinnati, OH 45241–2422.
16–069	Mepriam Tablets	Lemmon Co., 650 Cathill Rd., Sellersville, PA 18960.
16–379	Locorten Cream	Ciba Pharmaceuticals Division.
17–046	Kaon-Cl/Koan-Cl 10 Tablets	Savage Laboratories, Division of Altana Inc., 60 Baylis Rd., Melville, NY 11747.
17–244	Uticort Gel	Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Co., 2800 Plymouth Rd., Ann Arbor, MI 48105.
17–739	Monistat-Derm Lotion	The R.W. Johnson Pharmaceutical Research Institute, Route 202, P.O. Box 300, Raritan, NJ 08869–0602.
17–941	Sudafed 12–Hour Capsules	Burroughs Wellcome Co.
18–004	Hydroxyprogesterone Caproate Injection	Akorn Inc., P.O. Box 1220, Decatur, IL 62525.
18–009	Sarenin Injection	Procter & Gamble Pharmaceuticals.
18–075	K-TimeKap Capsules	Ciba Pharmaceuticals Division.
18–166	Trasicor Capsules	Do.
18–816	Micatin Antifungal Powder	Advanced Care Products, Ortho Pharmaceutical Corp., J&J Research Complex, Route 1 South and Middleton Rd., North Brunswick, NJ 08902–0724.
18–872	Viskazide Tablets	Sandoz Pharmaceuticals Corp., 59 Route 10, East Hanover, NJ 07936–1080.
19–208	Actifed Capsules	Burroughs Wellcome Co.
19–451	Lopressor Chlorthalidone Capsules	Ciba Pharmaceutials Division.
20–158	Deracyn Tablets	The Upjohn Co., U.S. Pharmaceutical Regulatory Affairs, 7000 Portage Rd., Kalamazoo, MI 49001–0199.
50–473	Velosef Powder for Oral Suspension	Apothecon.
50–474	Velosef Capsules	Do.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the NDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective September 29, 1995.

Dated: September 21, 1995.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 95–24158 Filed 9–28–95; 8:45 am]

BILLING CODE 4160–01–P

[Docket No. 95N–0319]

Roche Pharmaceutical Inc., et al.; Withdrawal of Approval of 13 New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 13 new drug applications (NDA's). The holders of the NDA's notified the agency in writing that the drug products were no longer being marketed under the NDA and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: September 29, 1995.

FOR FURTHER INFORMATION CONTACT: Nancy Maizel, Center for Drug Evaluation and Research (HFD–53), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2623.

SUPPLEMENTARY INFORMATION: The holders of the NDA's listed below have informed FDA that these drug products are no longer being marketed under the NDA and requested that FDA withdraw approval of the applications. The applicants have also, by request, waived their opportunity for a hearing.

NDA No.	Drug	Applicant
8–414	Gantrisin Ophthalmic Ointment	Roche Pharmaceuticals, Division of Hoffmann-La Roche Inc., 340 Kingsland St., Nutley, NJ 07110–1199.
18–996	Actifed 12–Hour Capsules	Burroughs Wellcome Co., 3030 Cornwallis Rd., P.O. Box 12700, Research Triangle Park, NC 27709–2700.
50–102	Dynapen for Injection	Apothecon, Bristol-Myers Squibb Co., P.O. Box 4500, Princeton, NJ 08543–4500.
50–117	Staphcillin Injection	Do.
50–118	Prostaphlin Capsules	Do.
50–167	Polysporin Aerosol Spray	Burroughs Wellcome Co.
50–176	Neosporin Cream	Do.
50–191	Tegopen Capsules	Apothecon.